Patents by Inventor Michael Wade

Michael Wade has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12446990
    Abstract: A medical body shield is provided, which includes a center panel formed from a visually-transparent material. The medical body shield protects a user from infectious diseases, while providing the physical access and manual dexterity needed to interact with one or more individuals who are infected (or suspected of being infected). The medical body shields may be used in methods of conducting testing and/or administering treatments.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: October 21, 2025
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Garry E. Shields, Michael Wade, James G. Mattern
  • Patent number: 12310992
    Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
    Type: Grant
    Filed: December 11, 2023
    Date of Patent: May 27, 2025
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Patent number: 12274684
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Grant
    Filed: December 11, 2023
    Date of Patent: April 15, 2025
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Publication number: 20240131078
    Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 25, 2024
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Publication number: 20240100003
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Application
    Filed: December 11, 2023
    Publication date: March 28, 2024
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Patent number: 11839631
    Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: December 12, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Patent number: 11839596
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: December 12, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Patent number: 11745309
    Abstract: A remotely operated abrasive blasting apparatus is provided. Systems incorporating the apparatus, and methods of treating surfaces using the apparatus and systems are also provided. The abrasive blasting apparatus eliminates the need for human operators to be present in the area being treated, and allows areas inaccessible to human operators to be treated.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: September 5, 2023
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventor: Michael Wade
  • Patent number: 11666602
    Abstract: The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 6, 2023
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Publication number: 20230112834
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 31, 2022
    Publication date: April 13, 2023
    Applicant: United Therapeutics Corporation
    Inventor: Michael WADE
  • Patent number: 11620893
    Abstract: Systems and apparatus are provided for monitoring and/or collecting data regarding environmental conditions and optionally personal health information, and generating warnings for a wearer based on acceptable limits for hazards. Using the collected data, the systems and apparatus communicate recommendations to the wearer to improve or maintain personal safety in the detected environment. Methods for monitoring environmental risks and generating warnings based on acceptable limits for hazards are also provided.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: April 4, 2023
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Michael Wade, Garry E. Shields, Zbigniew J. Karaszewski
  • Publication number: 20220062210
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Application
    Filed: September 8, 2021
    Publication date: March 3, 2022
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Publication number: 20210342404
    Abstract: Systems and methods for efficiently processing electronically stored information (ESI) are described. The systems and methods describe processing ESI in preparation for, or association with, litigation. The invention preserves the contextual relationships among documents when processing and indexing data, allowing for increased precision and recall during data analytics.
    Type: Application
    Filed: May 18, 2021
    Publication date: November 4, 2021
    Inventors: Michael WADE, Robert NELSON
  • Patent number: 11141393
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: October 12, 2021
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Patent number: 11113942
    Abstract: Systems and apparatus are provided for monitoring and/or collecting data regarding environmental conditions and optionally personal health information, and generating warnings for a wearer based on acceptable limits for hazards. Using the collected data, the systems and apparatus communicate recommendations to the wearer to improve or maintain personal safety in the detected environment. Methods for monitoring environmental risks and generating warnings based on acceptable limits for hazards are also provided.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: September 7, 2021
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Michael Wade, Garry E. Shields, Zbigniew J. Karaszewski
  • Publication number: 20210177787
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 25, 2021
    Publication date: June 17, 2021
    Applicant: United Therapeutics Corporation
    Inventor: Michael WADE
  • Patent number: 11036808
    Abstract: Systems and methods for efficiently processing electronically stored information (ESI) are described. The systems and methods describe processing ESI in preparation for, or association with, litigation. The invention preserves the contextual relationships among documents when processing and indexing data, allowing for increased precision and recall during data analytics.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: June 15, 2021
    Assignee: PLANET DATA SOLUTIONS
    Inventors: Michael Wade, Robert Nelson
  • Patent number: D1043023
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: September 17, 2024
    Assignee: Meso Scale Technologies, LLC.
    Inventors: Jacob N. Wohlstadter, Rodger Darin Osborne, Jennifer Parker, Aaron Leimkuehler, Manish Kochar, Peter Bosco, Michael Wade, Gary Krivoy
  • Patent number: D1047338
    Type: Grant
    Filed: December 27, 2021
    Date of Patent: October 15, 2024
    Assignee: MESO SCALE TECHNOLOGIES, LLC.
    Inventors: Jacob N. Wohlstadter, Rodger Darin Osborne, Jennifer Parker, Aaron Leimkuehler, Manish Kochar, Peter Bosco, Michael Wade, Gary Krivoy
  • Patent number: D1047339
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: October 15, 2024
    Assignee: MESO SCALE TECHNOLOGIES, LLC.
    Inventors: Jacob N. Wohlstadter, Rodger Darin Osborne, Jennifer Parker, Aaron Leimkuehler, Manish Kochar, Peter Bosco, Michael Wade, Gary Krivoy, Charles M. Clinton